Scaling the druggability landscape of human bromodomains, a new class of drug targets.
作者信息
Zhang Guangtao, Sanchez Roberto, Zhou Ming-Ming
机构信息
Department of Structural and Chemical Biology, Mount Sinai School of Medicine , 1425 Madison Avenue, New York, New York 10029, USA.
出版信息
J Med Chem. 2012 Sep 13;55(17):7342-5. doi: 10.1021/jm3011977. Epub 2012 Aug 28.
Abstract
摘要
相似文献
1
Scaling the druggability landscape of human bromodomains, a new class of drug targets.
J Med Chem. 2012 Sep 13;55(17):7342-5. doi: 10.1021/jm3011977. Epub 2012 Aug 28.
2
Druggability of methyl-lysine binding sites.
J Comput Aided Mol Des. 2011 Dec;25(12):1171-8. doi: 10.1007/s10822-011-9505-2. Epub 2011 Dec 7.
3
Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.
J Med Chem. 2016 Feb 25;59(4):1410-24. doi: 10.1021/acs.jmedchem.5b00209. Epub 2015 Apr 6.
4
Aim for the Readers! Bromodomains As New Targets Against Chagas' Disease.
Curr Med Chem. 2019;26(36):6544-6563. doi: 10.2174/0929867325666181031132007.
5
Lysine acetylation and the bromodomain: a new partnership for signaling.
Bioessays. 2004 Oct;26(10):1076-87. doi: 10.1002/bies.20104.
6
A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications.
Structure. 2015 Oct 6;23(10):1801-1814. doi: 10.1016/j.str.2015.08.004. Epub 2015 Sep 10.
7
Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300.
Structure. 2008 Apr;16(4):643-52. doi: 10.1016/j.str.2008.01.010.
8
Bromodomains as targets for therapeutic intervention.
Drug Discov Today Technol. 2016 Mar;19:1-2. doi: 10.1016/j.ddtec.2016.09.002.
9
Structural features and inhibitors of bromodomains.
Drug Discov Today Technol. 2016 Mar;19:3-15. doi: 10.1016/j.ddtec.2016.09.001. Epub 2016 Sep 22.
10
Interaction of propionylated and butyrylated histone H3 lysine marks with Brd4 bromodomains.
Angew Chem Int Ed Engl. 2010 Sep 10;49(38):6768-72. doi: 10.1002/anie.201002724.
引用本文的文献
1
New Approaches to Targeting Epigenetic Regulation in Bladder Cancer.
Cancers (Basel). 2023 Mar 20;15(6):1856. doi: 10.3390/cancers15061856.
2
Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs.
RSC Adv. 2020 Dec 24;11(2):612-636. doi: 10.1039/d0ra07971e.
3
Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents.
Molecules. 2022 Mar 31;27(7):2294. doi: 10.3390/molecules27072294.
4
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Future Sci OA. 2019 Jan 29;5(3):FSO372. doi: 10.4155/fsoa-2018-0115. eCollection 2019 Mar.
5
Chemical Space Expansion of Bromodomain Ligands Guided by in Silico Virtual Couplings (AutoCouple).
ACS Cent Sci. 2018 Feb 28;4(2):180-188. doi: 10.1021/acscentsci.7b00401. Epub 2018 Feb 7.
6
Protein dynamics and structural waters in bromodomains.
PLoS One. 2017 Oct 27;12(10):e0186570. doi: 10.1371/journal.pone.0186570. eCollection 2017.
7
Inhibitors of BRD4 Protein from a Marine-Derived Fungus Alternaria sp. NH-F6.
Mar Drugs. 2017 Mar 16;15(3):76. doi: 10.3390/md15030076.
8
Partners in crime: The role of tandem modules in gene transcription.
Protein Sci. 2015 Sep;24(9):1347-59. doi: 10.1002/pro.2711. Epub 2015 Jun 11.
9
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Oncotarget. 2015 Mar 20;6(8):5501-16. doi: 10.18632/oncotarget.3551.
10
The bromodomain: from epigenome reader to druggable target.
Biochim Biophys Acta. 2014 Aug;1839(8):676-85. doi: 10.1016/j.bbagrm.2014.03.011. Epub 2014 Mar 28.
本文引用的文献
1
Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites.
J Med Chem. 2012 Sep 13;55(17):7346-59. doi: 10.1021/jm300346w. Epub 2012 Jul 12.
2
A leap into the chemical space of protein-protein interaction inhibitors.
Curr Pharm Des. 2012;18(30):4648-67. doi: 10.2174/138161212802651571.
3
Modulating protein-protein interactions: from structural determinants of binding to druggability prediction to application.
Curr Pharm Des. 2012;18(30):4630-47. doi: 10.2174/138161212802651553.
4
Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition.
J Biol Chem. 2012 Aug 17;287(34):28840-51. doi: 10.1074/jbc.M112.359505. Epub 2012 May 29.
5
New insights from structural biology into the druggability of G protein-coupled receptors.
Trends Pharmacol Sci. 2012 May;33(5):249-60. doi: 10.1016/j.tips.2012.02.005. Epub 2012 Mar 30.
6
Histone recognition and large-scale structural analysis of the human bromodomain family.
Cell. 2012 Mar 30;149(1):214-31. doi: 10.1016/j.cell.2012.02.013.
7
Structure-based computational analysis of protein binding sites for function and druggability prediction.
J Biotechnol. 2012 Jun 15;159(3):123-34. doi: 10.1016/j.jbiotec.2011.12.005. Epub 2011 Dec 14.
8
Combining global and local measures for structure-based druggability predictions.
J Chem Inf Model. 2012 Feb 27;52(2):360-72. doi: 10.1021/ci200454v. Epub 2012 Jan 5.
9
DrugPred: a structure-based approach to predict protein druggability developed using an extensive nonredundant data set.
J Chem Inf Model. 2011 Nov 28;51(11):2829-42. doi: 10.1021/ci200266d. Epub 2011 Oct 13.
10
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Nature. 2011 Oct 2;478(7370):529-33. doi: 10.1038/nature10509.
Zotero 插件